Kraematon Investment Advisors, Inc Intellia Therapeutics, Inc. Transaction History
Kraematon Investment Advisors, Inc
- $92.7 Million
- Q2 2024
A detailed history of Kraematon Investment Advisors, Inc transactions in Intellia Therapeutics, Inc. stock. As of the latest transaction made, Kraematon Investment Advisors, Inc holds 9,815 shares of NTLA stock, worth $188,546. This represents 0.24% of its overall portfolio holdings.
Number of Shares
9,815
Previous 9,815
-0.0%
Holding current value
$188,546
Previous $270,000
18.89%
% of portfolio
0.24%
Previous 0.29%
Shares
9 transactions
Others Institutions Holding NTLA
# of Institutions
326Shares Held
88.8MCall Options Held
673KPut Options Held
865K-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl11.6MShares$223 Million2.36% of portfolio
-
Black Rock Inc. New York, NY9.6MShares$184 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.1MShares$175 Million0.0% of portfolio
-
Deep Track Capital, LP Greenwich, CT4.8MShares$92.2 Million3.53% of portfolio
-
State Street Corp Boston, MA4.36MShares$83.8 Million0.0% of portfolio
About Intellia Therapeutics, Inc.
- Ticker NTLA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 76,011,800
- Market Cap $1.46B
- Description
- Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...